CEL-SCI FY26 Q3 net loss narrows to USD 5.7 million; loss per share improves to USD 0.47
CVM•Cash use and financing during the quarter
Operating cash outflow totaled USD 4 million; gross proceeds of about USD 9.7 million were raised during the quarter.
Quarterly results improve as loss narrows
CEL-SCI posted a net loss of USD 5.7 million for the quarter ended June 30, 2026; basic and diluted loss per share narrowed to USD 0.47.
Research and development expense edged down to USD 3.6 million; general and administrative costs rose to USD 1.9 million.
Multikine study plans and potential regulatory path
The company plans to start global enrollment in a 212-patient FDA confirmatory registration study for Multikine; early pre-surgical tumor responses may support accelerated approval.
Partnership for Saudi approval and commercialization
CEL-SCI entered a partnership with Amarox to seek Saudi approval and commercialization of Multikine, with a 50/50 net revenue split.
